Sareum Holdings plc (AIM:SAR)
London flag London · Delayed Price · Currency is GBP · Price in GBX
16.50
-0.50 (-3.03%)
Aug 8, 2025, 4:35 PM GMT+1

Sareum Holdings Company Description

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases.

The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases.

It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms.

Sareum Holdings plc was formerly known as Keepfast plc and changed its name to Sareum Holdings plc in July 2004.

The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.

Sareum Holdings plc
CountryUnited Kingdom
Founded2004
IndustryBiotechnology
SectorHealthcare
Employees5

Contact Details

Address:
Langford Arch
Cambridge, CB22 3FX
United Kingdom
Phone44 1223 497 700
Websitesareum.com

Stock Details

Ticker SymbolSAR
ExchangeLondon Stock Exchange AIM
Fiscal YearJuly - June
Reporting CurrencyGBP
ISIN NumberGB00BMC3RJ87
SIC Code2834